Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with an
average 5-year survival rate of less than 10%. Unfortunately, the majority of patients have …

Despite decades of research, pancreatic ductal adenocarcinoma (PDAC) continues to have
the worst 5-year survival of any malignancy. With 338,000 new cases diagnosed and over …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of
pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional
treatments, although a limited number of early-stage patients can undergo radical resection …

The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers
with very few available treatments. For many decades, gemcitabine was the only treatment …

The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) is non-
immunogenic, which consists of the stellate cells, fibroblasts, immune cells, extracellular …

The genomic-plasticity of the immune system creates a broad immune repertoire engaged to
tackle cancer cells. Promising clinical activity has been observed with several immune …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …